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Objective: Prior studies investigating the association between APOE alleles e2/e4 and risk of intracerebral
hemorrhage (ICH) have been inconsistent and limited to small sample sizes, and did not account for confounding by
population stratification or determine which genetic risk model was best applied.
Methods: We performed a large-scale genetic association study of 2189 ICH cases and 4041 controls from 7
cohorts, which were analyzed using additive models for e2 and e4. Results were subsequently meta-analyzed using a
random effects model. A proportion of the individuals (322 cases, 357 controls) had available genome-wide data to
adjust for population stratification.
Results: Alleles e2 and e4 were associated with lobar ICH at genome-wide significance levels (odds ratio [OR] ¼ 1.82,
95% confidence interval [CI] ¼ 1.50–2.23, p ¼ 6.6  1010; and OR ¼ 2.20, 95%CI ¼ 1.85–2.63, p ¼ 2.4  1011,
respectively). Restriction of analysis to definite/probable cerebral amyloid angiopathy ICH uncovered a stronger
effect. Allele e4 was also associated with increased risk for deep ICH (OR ¼ 1.21, 95% CI ¼ 1.08–1.36, p ¼ 2.6 
104). Risk prediction evaluation identified the additive model as best for describing the effect of APOE genotypes.
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Interpretation: APOE e2 and e4 are independent risk factors for lobar ICH, consistent with their known associations
with amyloid biology. In addition, we present preliminary findings on a novel association between APOE e4 and
deep ICH. Finally, we demonstrate that an additive model for these APOE variants is superior to other forms of
genetic risk modeling previously applied.
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Intracerebral hemorrhage (ICH) accounts for approxi-mately 15% of acute strokes in the United States1 and
carries the worst prognosis of all acute cerebrovascular dis-
eases. Even with state-of-the-art medical care, ICH results
in death or severe disability in more than 50% of cases.2,3
The e2 and e4 alleles of Apolipoprotein E (APOE)
have been reported to be associated with risk of ICH in
several small studies and meta-analyses,4,5 but results
thus far have been inconsistent.6–9 In a recent meta-anal-
ysis of the role of APOE in ICH,5 the largest study
included 333 ICH cases and the smallest contributed 48.
Furthermore, previous reviews compiled data from pub-
lished reports rather than perform meta-analysis of indi-
vidual-level data.
Previous results suggest that the degree of associa-
tion between APOE and ICH might depend on hemor-
rhage location: most studies have shown associations
between e2/e4 and lobar ICH, while results for nonlobar
ICH have been contradictory.4–6 Despite these observa-
tions of location-specific effects, only 4 cohorts in the
latest meta-analysis5 provided association results by ICH
location for APOE variants (244 lobar ICH cases, 437
nonlobar ICH cases).
Possible confounding for reported associations
between APOE and ICH has not been extensively
explored. Population stratification (the phenomenon by
which genetic ancestry imbalance between cases and con-
trols generates a false-positive association) is a particularly
concerning potential confounder, given the variation in
APOE minor allele frequencies (MAFs) worldwide.10
Previous results could also have been distorted by inap-
propriate genetic modeling. Published studies have con-
sistently applied a dominant genetic model to all analy-
ses,4,5 despite limited data for correspondence between
this genetic model and the biological effects of APOE.
We performed a large-scale multicenter genetic
association study to clarify these issues, capitalizing on
the resources and infrastructure available to investigators
within the International Stroke Genetics Consortium
(ISGC). We pooled cases (n ¼ 2189) and controls (n ¼
4041) with neuroimaging-confirmed hemorrhage location
for analysis and used genome-wide genetic data available
for 322 cases and 357 controls to investigate and rule
out population stratification as a possible source of con-
founding. Finally, we tested various genetic models to
clarify the influence of e2 and e4 alleles on ICH risk.
Patients and Methods
Participating Studies
Genotype and phenotype data for ICH cases and controls were
provided by ISGC investigators from the following studies:
North American (United States) multicenter Genetics of Cere-
bral Hemorrhage on Anticoagulation (GOCHA) Study,11
Genetic and Environmental Risk Factors for Hemorrhagic
Stroke (GERFHS), University of Cincinnati (Cincinnati,
OH),12 the Hospital del Mar (Barcelona, Spain) ICH study
(HM-ICH),13 Jagiellonian University (Krakow, Poland) Hemor-
rhagic Stroke Study (JUHSS),14 Lund University (Lund, Swe-
den) Hemorrhagic Stroke Study (LUHSS),15 Medical University
of Graz (Graz, Austria) ICH study (MUG-ICH),16 and the
Vall d’Hebron Hospital (Barcelona, Spain) ICH Study (VHH-
ICH).17 All studies were approved by the Institutional Review
Boards (IRB) or Ethics Committee (EC) of participating insti-
tutions, and all participating subjects provided informed con-
sent for participation in this study, including APOE and ge-
nome-wide genotyping.
Subjects
Subjects enrolled in each study included primary acute ICH cases
aged >55 years presenting to the emergency departments of par-
ticipating institutions (all accredited stroke centers). Eligibility
for study participation required neuroimaging (CT or MRI) con-
firmation of hemorrhagic stroke (Table 1). Exclusion criteria
included the presence of trauma, brain tumor, hemorrhagic trans-
formation of a cerebral infarction, vascular malformation, or any
other perceived cause of secondary ICH. Only individuals of self-
described European or European-American ancestry were included
for analysis in each study. Individuals of African-American ancestry
(63 lobar ICH cases, 110 deep ICH cases, and 297 controls) en-
rolled in GOCHA and GERFHS were analyzed as a separate
cohort (US-AA) for replication purposes, with additional adjust-
ment for recruitment site (GOCHA vs GERFHS).
ICH location was assigned based on admission CT scan
by stroke neurologists at each participating site. ICH isolated to
the cortex (with or without involvement of subcortical white
matter) was defined as lobar ICH, while ICH selectively involv-
ing the thalamus, basal ganglia, or brainstem was defined as
deep (nonlobar) ICH. Multiple concurrent bleeds involving
deep and lobar territories were defined as mixed ICH and rep-
resented an exclusion criterion. Similarly, subjects presenting
with evidence of prior bleeds in a different location than the
index (enrollment) ICH were excluded from analysis. Cerebellar
hemorrhages were also not analyzed in the present study. Indi-
viduals with CT scans of insufficient quality for location deter-
mination were excluded from all analyses. When ICH location
assignment was not clear, the scan was reviewed by a group of
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study neurologists and neuroradiologists for consensus. Scans
lacking a consensus location were excluded from analysis. All
readers interpreting neuroimaging data were blinded to clinical
and APOE genotype information.
Recorded clinical characteristics included history of
hypertension (clinical diagnosis of hypertension or history of
antihypertensive drug use), pre-ICH exposure to warfarin, anti-
platelet agents and statins, first-degree relative history of ICH,
and alcohol and tobacco use.
Controls were enrolled from the same population as the
cases at each participating institution, and included only indi-
viduals aged >55 years at time of enrollment. Controls were
confirmed to have no medical history of ICH, Alzheimer’s dis-
ease, or pre-enrollment dementia by means of interview and
review of medical records. Recorded clinical characteristics were
identical to ICH cases.
Cerebral Amyloid Angiopathy-Related ICH
In order to determine the specificity of APOE alleles for ICH
related to cerebral amyloid angiopathy (CAA), we separately ana-
lyzed definite and/or probable CAA ICH cases and possible CAA
cases for association with e2 or e4. A total of 223 lobar ICH cases
from the GOCHA cohort had pathology and/or MRI gradient-
echo (GRE) data available for analysis. Microbleed presence and
location was assessed for these individuals according to validated
protocols.18,19 Briefly, MRI with GRE images (repetition time
[TR] ¼ 750msec/echo time [TE] ¼ 50msec/slice thickness ¼ 5–
6mm/interslice gap ¼ 1mm ) was performed using a 1.5-T mag-
net. Cortical (lobar) and deep hemorrhages were classified as
microbleeds according to their size (diameter < 5mm). All MRI
analyses were performed and recorded without knowledge of clini-
cal or genetic information. Only MRI scans obtained within 90
days from the index ICH were considered for analysis.
Definite/probable CAA was defined as lobar ICH in the
presence of confirmed CAA pathology20 and/or microbleeds
confined to the lobar brain region (n ¼ 82).21 Possible CAA
included all remaining lobar ICH cases lacking CAA pathology
and lobar microbleeds (n ¼ 141). Each group was matched
with separate hemorrhage-free controls based on age (within 5
years of the age of the index ICH case), gender, and hyperten-
sion status in a 1:2 case:control ratio.
Genotyping
All DNA samples were isolated from fresh or frozen blood,
quantified using a quantification kit and normalized to a con-
centration of 30ng/ll. Two genotype-determining variants in
APOE, rs7412, and rs429358, were independently genotyped
using 2 separate assays.21 The allelic reads from the 2 assays
were then translated to APOE genotypes (e3e3, e3e4, e4e4,
e3e2, e2e2, and e2e4). All genotyping personnel were blinded
to clinical and neuroimaging data. Genotype and phenotype
data were subsequently submitted to the Coordinating Center
(Massachusetts General Hospital) for analysis. All case and con-
trol groups were found to be in Hardy-Weinberg equilibrium
for APOE genotypes. Genome-wide genotyping was performed
on a subset of the GOCHA samples (322 cases, 357 controls)
using the Illumina 610-Quad array. Genotypes were called
using BeadStudio v 3.2.
Statistical Analysis
INDIVIDUAL STUDIES. Single-study level data were initially
analyzed by logistic regression under independent additive genetic
models. Our multivariate model included the following variables:
age, gender, pre-ICH history of hypertension, number of e4 al-
leles (0, 1, or 2), and number of e2 alleles (0, 1, or 2). Subsequent
analyses also adjusted for warfarin or antiplatelet agent exposure
at time of ICH, smoking history (ever smoker), alcohol use (>1
drink/week), family history of ICH, pre-ICH history of ischemic
stroke, and pre-ICH history of hyperlipidemia or statin exposure.
None of the additional covariates modified the results from the
initial regression model (data not shown). We therefore extracted
results from the previously described model (adjusting for age,
gender, and pre-ICH hypertension) for subsequent meta-analysis
(see Meta-Analysis). Differences in effect sizes comparing lobar vs
deep ICH and definite/probable CAA vs possible CAA were
assessed using the Breslow-Day test.
META-ANALYSIS. Results from multivariate models for
individual studies were combined using a conservative inverse
variance random effects model (DerSimonian-Laird). Results
from individuals with genome-wide data were entered separately
as an independent study. This allowed direct comparison of
results from studies controlling for population stratification
with those without control. Meta-analysis heterogeneity was
quantified by computing Cochrane’s Q and corresponding p
and I2 (percent of effect size attributable to heterogeneity). Het-
erogeneity was considered to be significant for heterogeneity p
< 0.10 (due to the conservative nature of Cochrane’s test) or I2
> 0.20. We decided to set the threshold for significance in the
initial meta-analysis at the genome-wide level (p < 5  108).
This threshold is equivalent to the estimated Bonferroni correc-
tion for all independently testable common variants (minor al-
lele frequency > 0.01) in the human genome (ie, not correlated
by linkage disequilibrium on the basis of HapMap and
sequencing data).22 All analyses were performed using the R
statistical software v 2.10.0 (http://www.r-project.org).
GENETIC MODELING. We reanalyzed all available data
under dominant and recessive models, and compared predictive
power for disease status to the initial results from the additive model.
Comparison of predictive power for different genetic models was
carried out using both a likelihood ratio test (LRT)-based method
and by analyzing receiver operator characteristic (ROC) curves for
disease status prediction. Both analyses returned very similar results.
POPULATION STRATIFICATION. To determine whether
the frequency of APOE alleles varies across different popula-
tions, a finding that could lead to confounding due to popula-
tion stratification, we extracted MAF data for European control
individuals from all genetic studies of APOE listed in PubMed
(www.pubmed.gov) as of December 1, 2010 (Supporting Table
S1). These data were subsequently correlated with latitude and
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longitude of their geographic position in Europe using a linear
regression method. This analysis included size of the cohort
and number of studies performed in each region as covariates.
We were able to control for population stratification in
samples with available genome-wide data (322 cases, 357 controls)
using PLINK v. 1.07 (http://pngu.mgh.harvard.edu/purcell/
plink) to perform principal component analysis (PCA) in accord-
ance with previously published methods.23 Principal components
1 and 2 were extracted from the PCA results and entered as addi-
tional covariates in logistic regression analysis for these samples.
Results
Lobar ICH
We meta-analyzed 931 lobar ICH cases and 3744 con-
trols from 7 studies, and found significant genome-wide
association between lobar ICH risk and e2 (odds ratio
[OR] ¼ 1.82, p ¼ 6.6  1010) and e4 (OR ¼ 2.20,
p ¼ 2.4  1011) (Fig 1A, B). We identified no evi-
dence of heterogeneity among studies (Table 2).
We separately analyzed definite/probable CAA ICH
cases (n ¼ 82) and possible CAA ICH cases (n¼ 141) sam-
ples in the subset of the GOCHA lobar ICH cases with avail-
able pathology and/or MRI data (n ¼ 223). We then com-
pared effect sizes in order to determine the specificity of the
APOE association to definite/probable CAA (Table 3). Defi-
nite/probable CAA was associated with both e4 (OR ¼ 3.08,
p< 0.001) and e2 (OR¼ 2.89, p< 0.001), while no associ-
ation was evident for possible CAA (e4: OR ¼ 1.21, p ¼
0.46; and e2: OR ¼ 1.02, p ¼ 0.57). Effect-size point esti-
mates and 95% confidence intervals [CIs] were significantly
larger for definite/probable CAA ICH compared to possible
CAA ICH for both e4 (p¼ 0.012) and e2 (p¼ 0.032).
Deep ICH
We meta-analyzed 1085 deep ICH cases and 3657 controls
from 6 studies, and found an association between deep ICH
risk and e4 (OR ¼ 1.21, 95% CI ¼ 1.08–1.36). This asso-
ciation failed to surpass the predefined genome-wide
FIGURE 1: Forest plots of meta-analysis of APOE in (A, B) lobar ICH and (C, D) deep ICH.
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significance threshold (p ¼ 2.6  104). No association was
identified for e2 (OR ¼ 1.07, 95% CI ¼ 00.86–1.33, p ¼
0.54) (see Fig 1C, D). We identified no evidence of meta-
analysis heterogeneity (see Table 2). To explore whether the
inclusion of misclassified lobar ICH cases in the group of
deep ICH category might have generated a spurious associa-
tion for e4, we reanalyzed brainstem ICH cases (less likely to
represent misdiagnosed lobar ICH due to the anatomic loca-
tion and smaller average ICH volume) separately from the
rest of the deep ICH cases. We then compared effect sizes
and looked for meta-analysis heterogeneity that might indi-
cate differential effects due to misclassification bias. The OR
for e4 in brainstem ICH (OR ¼ 1.21) was identical to our
meta-analysis estimate for deep ICH, and we identified no
evidence of heterogeneity between studies (heterogeneity p ¼
0.99, I2 ¼ 0.00, 95% CI ¼ 0.00–0.00). Comparison of
effect sizes for e4 in lobar ICH vs deep ICH resulted in a sta-
tistical significant difference (p < 0.001).
Replication in African-American Individuals
We attempted replication of observed associations in 63
lobar ICH cases, 110 deep ICH cases, and 297 controls
of U.S. African-American ancestry (US-AA) enrolled in
GOCHA and GERFHS. We observed replication of
associations between lobar ICH and both e2 (OR ¼
1.99, 95% CI ¼ 1.10–3.61, p ¼ 0.036) and e4 (OR ¼
2.10, 95% CI ¼ 1.09–4.03, p ¼ 0.012). Inclusion of
US-AA samples in meta-analysis with European ancestry
samples did not introduce significant heterogeneity (p ¼
0.99, I2 ¼ 0.0). While we did not replicate the
TABLE 2: Meta-Analysis: Association of APOE Alleles with Lobar and Deep ICH
Cases Controls OR 95% CI OR p Heterogeneity
p
I2 (95% I2 CI)
Lobar ICH
Allele
e2 931 3744 1.82 1.50–2.23 6.6  1010 0.98 0.00 (0.00–0.00)
e4 931 3744 2.20 1.85–2.63 2.4  1011 0.99 0.00 (0.00–0.00)
Deep ICH
Allele
e2 1085 3657 1.07 0.86–1.33 0.54 0.95 0.00 (0.00–0.00)
e4 1085 3657 1.21 1.08–1.36 2.6  104 0.97 0.00 (0.00–0.00)
CI ¼ confidence interval; ICH ¼ intracerebral hemorrhage, I2 ¼ percentage of meta-analysis effect size due to heterogeneity;
OR ¼ odds ratio.









e2 82 164 0.18 0.07 2.89 1.57–5.33 5.2  104
e4 82 164 0.25 0.12 3.08 1.68–5.63 4.6  104
Possible CAA ICH
Allele
e2 141 282 0.09 0.07 1.02 0.63–1.65 0.57
e4 141 282 0.16 0.12 1.21 0.74–1.99 0.46
See Woo et al.12
CAA ¼ cerebral amyloid angiopathy; CI ¼ confidence interval; ICH ¼ intracerebral hemorrhage; MAF ¼ minor allele frequency;
OR ¼ odds ratio.
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association between e4 and deep ICH (p ¼ 0.21), the
effect size estimate (OR ¼ 1.15) was consistent with that
observed in the European ancestry samples. Inclusion of
US-AA samples in the deep ICH meta-analysis did not
introduce significant heterogeneity (p ¼ 0.99, I2 ¼ 0.0)
and increased the level of significance of the observed
association (p-value for all individuals ¼ 1.0  104 vs
p-value for Europeans only ¼ 2.6  104)
Genetic Model Specification
We repeated all analyses for lobar ICH under dominant and
recessive genetic models and compared predictive perform-
ance with the additive model based on individual genotypes.
Significance was assessed using the LRT and comparing
ROC curves. Disease status (lobar ICH case vs control) pre-
diction was significantly more accurate for the additive
model compared to the dominant model (LRT: p < 0.0001;
ROC: p < 0.0001) or the recessive model (LRT: p ¼
0.0002; ROC: p ¼ 0.0001). This was reflected in the pre-
dicted disease risk by APOE genotype, showing an increased
risk for e4/e4, e4/e2, and e2/e2 over the e3 heterozygote ge-
notypes (Fig 2A). We performed an identical analysis for
deep ICH: results obtained under different models revealed
superior predictive performance for the additive model over
dominant (LRT: p ¼ 0.001; ROC: p ¼ 0.003) or recessive
(LRT: p ¼ 0.0002; ROC: p ¼ 0.0001) models (see Fig 2B).
Population Stratification at the APOE Locus
The APOE locus demonstrated significant population
stratification across the European continent in our review
of previously published reports. e2 was associated with
both latitude (p ¼ 0.025) and longitude (p ¼ 0.001)
across the European continent, while e4 was associated
with latitude (p < 0.001). Observed MAFs ranged from
0.01 (Siberia) to 0.15 (UK) for e2 and from 0.06
(Southern Italy) to 0.27 (Finland) for e4 (Fig S1).
We therefore reanalyzed lobar and deep ICH
GOCHA individuals with genome-wide association
(GWAS) data (GOCHA-GWAS), comparing results
before and after inclusion of principal components. For
lobar ICH, the results for GOCHA-GWAS (181 cases,
357 controls) were very similar before (e2: OR ¼ 1.89,
p ¼ 0.012; e4: OR ¼ 2.28, p ¼ 0.010) and after (e2:
OR ¼ 1.88, p ¼ 0.010; e4: OR ¼ 2.28, p ¼ 0.009)
inclusion of principal components. No difference in
results was evident for deep ICH (141 cases, 357 con-
trols) comparing unadjusted (e2: OR ¼ 0.99, p ¼ 0.67;
e4: OR ¼ 1.19, p ¼ 0.14) and PCA-adjusted analyses
(e2: OR ¼ 0.98, p ¼ 0.54; e4: OR ¼ 1.18, p ¼ 0.15).
Discussion
Our analyses show strong associations between APOE
variants and lobar ICH, providing the first evidence of
association between sequence variants and intracerebral
hemorrhage that surpass the genome-wide significance
threshold. Furthermore, we have demonstrated that pre-
viously adopted genetic models of APOE and ICH
(dominant and recessive) do not provide the best possible
description of the increase in ICH risk associated with
the e2 and e4 alleles. This additional finding is impor-
tant for follow-up studies of the APOE locus, as it sup-
ports the existence of a dose-response relationship
between the biological effect of APOE and lobar ICH
risk, which is poorly understood at present. Finally,
although APOE MAF clearly varies across populations,
we were able to rule out population stratification as a
possible source of confounding.
We have also found that the effect of e2 and e4 in
lobar ICH appears to be predominantly associated with
CAA-related ICH. The increase in effect size observed
when analysis is restricted to definite/probable CAA sug-
gests that different mechanisms account for hemorrhagic
stroke in the presence or absence of pathological and
neuroimaging markers of amyloid angiopathy.24 Of note,
effect sizes associated with definite/probable CAA-related
ICH are in line with those observed for e4 in Alzheimer’s
disease,25 consistent with the existence of shared biologi-
cal pathways between the 2 conditions that do not neces-
sarily extend to lobar ICH as a whole.
We found an association between e4 APOE and
deep ICH, although it did not achieve genome-wide sig-
nificance. Previous findings in the PROGRESS trial
implicated APOE variants in deep ICH, particularly in
subjects of Asian ancestry.6 Our data extend this associa-
tion to European-ancestry individuals. We are not able to
rule out the possibility that lobar or CAA-related hemor-
rhages misclassified as deep hemorrhage might have gen-
erated a spurious association with e4. However, our ob-
servation that e4 is associated with brainstem ICH, with
an effect size identical to that observed in the deep ICH
cohort as a whole, supports the presence of a more fun-
damental mechanism linking e4 and non-CAA-related
ICH. APOE plays a critical role in redistributing lipids
among central nervous system cells for normal lipid ho-
meostasis,26,27 repairing injured neurons,28 maintaining
synaptodendritic connections,29 neurite outgrowth,30 syn-
aptic plasticity,31 mitochondrial resistance to oxidative
stress,32 and glucose use by neurons and glial cells.33–35
In multiple pathways affecting neuropathology, APOE e4
acts directly or in concert with age, head injury, oxidative
stress, ischemia, and inflammation to alter disease onset,
ANNALS of Neurology
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progression, and prognosis.36 Mechanisms such as these
could be involved in determining individual responses to
ICH-associated oxidative and ischemic stress, driving the
increased frequency of e4 in deep ICH cases. Indeed,
these biological phenomena could potentially play a role
in both lobar and deep ICH. Future studies, however,
will be required to clarify the biological implications of
our findings.
Our review of publicly available data on APOE al-
lele frequencies in Europeans confirmed an association
between geography and the e2/e4 genotype. This obser-
vation raises the possibility of confounding due to
FIGURE 2: Effect of APOE genotype on predicted probability of ICH status vs control. (A) Lobar ICH probability. (B) Deep ICH
probability. Box plots display the median (solid line), interquartile range (box), and total range (whiskers) of probability
distribution for each genotype. Disease status probability based on meta-analysis of logistic regression analyses from
individual studies under the assumption of the additive model, including adjustment for age, gender, hypertension, and
principal components (where available).
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population stratification in our analyses. We were able to
conclusively rule out population stratification only in the
GOCHA-GWAS dataset via PCA. However, effect-size
estimates within the GOCHA-GWAS data are entirely in
line with those observed in the cohorts without popula-
tion stratification control. This observation is inconsis-
tent with the hypothesis that observed associations for
APOE are due to confounding by population stratifica-
tion. Furthermore, we provide evidence of replication in
African Americans, in whom minor allele frequencies for
e2 and e4 are different from those in European-ancestry
cohorts (see Table 1). In light of these results, confound-
ing due to population stratification is theoretically possi-
ble but unlikely in our analyses.
Prior meta-analyses of the effect of APOE alleles on
ICH risk failed to identify genome-wide significant asso-
ciations with lobar ICH or any role for e4 in deep
ICH.4,5 However, all studies included in prior meta-anal-
yses had substantial limitations. Sample sizes were smaller
compared to the present study, and the vast majority of
individuals did not have ICH location information avail-
able for analysis, which likely resulted in loss of statistical
power given the divergent effect sizes for both APOE al-
leles in deep and lobar ICH. Furthermore, prior studies
and meta-analyses applied the dominant genetic model
in their description of the effects of APOE alleles on
ICH risk. Our own data demonstrate that the additive
model is superior to the dominant model in the descrip-
tion of genetic risk at APOE. Model misspecification in
prior studies likely further eroded statistical power.
Finally, previous meta-analyses did not have direct access
to individual-level data, thus limiting the harmonization
in statistical methods that we employed in our study.
Our study has limitations. Despite the large num-
ber of cases and controls available for analysis, the associa-
tion between e4 and deep ICH did not achieve genome-
wide significance. This result, therefore, must be consid-
ered preliminary. Similarly, while we were able to observe
a significant difference in effect size for e2 and e4 when
comparing definite/probable vs possible CAA, we do not
have sufficient power to rule out any effect in the latter.
Indeed, the estimated OR for e4 in possible CAA-related
ICH is very close to the one observed for deep ICH,
thereby raising the possibility of shared mechanism
between non CAA-related effects in both locations.
In summary, we have identified genome-wide sig-
nificant associations between APOE e2 and e4 and lobar
ICH. Additionally, we report preliminary findings on a
novel association between e4 and deep ICH. Future stud-
ies will be required to clarify the functional mechanisms
underlying the effect of APOE variants on ICH.
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